Patents Examined by George W Kosturko
  • Patent number: 11318136
    Abstract: Compositions for inhibiting the aggregation of a granin from a non-toxic low molecular weight form to a toxic high molecular weight aggregated form and/or dissociating a high molecular weight aggregated form to a low molecular weight form are provided. Such a composition typically includes one or more active compounds or agents, which may also be referred to herein as disaggregation compounds. Using the compounds and compositions described herein, methods of i) modulating, inhibiting or preventing the interaction of granins with metal ions, ii) modulating, inhibiting, preventing the aggregation of granins or dissociating aggregated granins, iii) reducing or inhibiting cell toxicity, iv) treating or preventing dementia or Alzheimer's disease, and v) preventing or treating Parkinson's and/or Huntington's diseases are also provided.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: May 3, 2022
    Inventor: Seung Hyun Yoo
  • Patent number: 11311518
    Abstract: Disclosed are the injection compositions of ?3 adrenoreceptor agonists such as mirabegron or their pharmaceutically acceptable salts or solvates or esters thereof. The present invention also relates to methods for preparing injection compositions and methods of using these dosage forms for the treatment of obesity, other related metabolic diseases, and reduction/removal of fat. The injection compositions as per the present invention have advantages of simple preparation, simple and convenient application, easy absorption, and better effect of treating. The compositions can also be used in cases where oral administration of the drug is not possible due to underlying conditions or concerns around inadequate oral absorption. The injection compositions as per the present invention have desirable pharmaceutical technical attributes.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: April 26, 2022
    Assignee: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Tusharmouli Mukherjee, Nagabasayya R Chikkamath
  • Patent number: 11304943
    Abstract: The invention is based on the finding that co-administration of 6-?-naltrexol alongside vitamin D together with a chemotherapeutic agent, results in a further reduction in lung cancer cell growth. The combination of 6-?-naltrexol with vitamin D results in a greater decrease in the growth of cancer cells compared to the sum of the effects of each agent when administered in isolation.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 19, 2022
    Assignee: LDN PHARMA LIMITED
    Inventors: Angus Dalgleish, Wai Lui
  • Patent number: 11304962
    Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: April 19, 2022
    Assignee: COVIS PHARMA GMBH
    Inventors: Robert Birch, Michael J. Jozwiakowski
  • Patent number: 11298329
    Abstract: The present invention is directed to antiviral compositions that provide efficacy against non-envelope viruses such as noroviruses. The antiviral compositions comprise an alkyl 2-hydroxycarboxylic acid and an effective amount of a sulfonated surfactant. The composition may be used as a topical on human skin, as a hand sanitizer or as a hard surface cleaning composition.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: April 12, 2022
    Assignee: ECOLAB USA INC.
    Inventors: Daniel E. Pedersen, Hilina Emiru, Carter Martin Silvernail
  • Patent number: 11285145
    Abstract: Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein. Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant. Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone.
    Type: Grant
    Filed: May 26, 2021
    Date of Patent: March 29, 2022
    Assignee: Corcept Therapeutics Incorporated
    Inventors: Hazel Hunt, Joseph Custodio
  • Patent number: 11278524
    Abstract: The present invention is directed to a formulation for treating cancer comprising an androgen receptor signaling inhibitor and a B-cell-lymphoma-2 inhibitor, which may further comprising a Bromodomain-and-Extra-Terminal protein inhibitor or a phosphoinositide 3-kinase inhibitor.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 22, 2022
    Assignee: STEMIRNA (SHANGHAI) BIOTECHNOLOGY CO. LTED.
    Inventors: Dean G. Tang, Xin Chen
  • Patent number: 11278546
    Abstract: A method for preventing and/or treating fibrosis associated with an eye-related disease or disorder includes administering an effective amount of a multikinase inhibitor to a subject in need thereof. The multikinase inhibitor is nintedanib, lenvatinib, a combination thereof, or a salt thereof. The eye-related disease or disorder is corneal transparency, corneal scar formation, secondary cataract formation, glaucoma filtration surgery, ocular surgical procedures and implants, photorefractive keratectomy, laser in situ keratomileusis, formation and contraction of pre- and epiretinal membranes, proliferative vitreoretinopathy, subretinal fibrosis/scarring, retinal gliosis, or formation of choroidal membranes.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 22, 2022
    Assignee: AIVIVA BIOPHARMA, INC.
    Inventors: Diane Tang-Liu, Gerald Woodrow Devries, Tiffany Constance Liu
  • Patent number: 11273157
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: March 15, 2022
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • Patent number: 11273158
    Abstract: The present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: March 15, 2022
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Lisa L. von Moltke, Peter J. Weiden, Marjie L. Hard
  • Patent number: 11253487
    Abstract: The present invention provides a method for safe and efficacious administration of esketamine.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: February 22, 2022
    Assignee: CLEXIO BIOSCIENCES LTD.
    Inventors: Elena Kagan, Gina Pastino
  • Patent number: 11229642
    Abstract: Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: January 25, 2022
    Assignee: BeyondSpring Pharmaceuticals, Inc.
    Inventors: Lan Huang, George Kenneth Lloyd, Ramon Mohanlal
  • Patent number: 11224588
    Abstract: The present invention relates to a combination of lipoic acid and taurine for use as an osmoprotective agent for the prevention and treatment of ailments of the skin and of the mucous membranes associated with osmotic imbalance. It also relates to a method for preventing and treating ailments of the skin and of the mucous membranes associated with osmotic imbalance, in which an appropriate amount of a combination of lipoic acid and taurine is applied to the skin or the mucous membranes of a patient who is in need thereof. The invention also relates to a pharmaceutical or cosmetic composition suitable for topical application or an oph-thalmic composition which comprises a combination oflipoic acid and taurine.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: January 18, 2022
    Assignee: OPHTALMIS MONACO
    Inventors: Martine Claret, Claude Claret, Caroline Chatard-Baptiste
  • Patent number: 11213501
    Abstract: A compounded transdermal cream for the topical administration of a compounded therapy includes a first active agent selected from the group consisting of nabumetone in an amount between approximately 5.0% and approximately 25% by weight of the transdermal cream and amitriptyline in an amount between approximately 0.5% and approximately 4.0% by weight of the transdermal cream; a second active agent comprising a nerve depressant in an amount between approximately 5.0% and 15.0% by weight of the transdermal cream, wherein the nerve depressant is gabapentin; a third active agent comprising a local anesthetic in an amount between approximately 1.0% and approximately 7.0% by weight of the transdermal cream, wherein the local anesthetic comprises lidocaine and prilocaine; and dimethyl sulfoxide (DMSO).
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: January 4, 2022
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 11213538
    Abstract: To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: January 4, 2022
    Assignees: GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Akira Asai, Naohisa Ogo, Daisuke Muraoka, Hiroshi Shiku, Naozumi Harada
  • Patent number: 11213495
    Abstract: The present invention relates to a method for decreasing the psychotomimetic side effects and enhancing the antidepressant-like effects of ketamine by the combination of ketamine with a methylglycine derivative. The present invention also relates to a method for depression treatment comprising administrating ketamine combined with a methylglycine derivative. The present invention further provides a method for preventing or treating addictive disorders of ketamine by administrating a methylglycine derivative.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: January 4, 2022
    Assignee: NATIONAL HEALTH RESEARCH INSTITUTES
    Inventor: Hwei-Hsien Chen
  • Patent number: 11213500
    Abstract: A compounded transdermal cream for topical administration of a compounded therapy includes a nerve depressant such as gabapentin in an amount between approximately 5% and 15% by weight of the transdermal cream, an NSAID (Non-Steroidal Anti-Inflammatory Drug) such as nabumetone in an amount between approximately 5% and approximately 25% by weight of the transdermal cream, a tricyclic antidepressant such as amitriptyline in an amount between approximately 0.5% and approximately 4% by weight of the transdermal cream, a local anesthetic such as lidocaine and prilocaine in an amount between approximately 1% and approximately 7% by weight of the transdermal cream, and dimethyl sulfoxide (DMSO).
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: January 4, 2022
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 11191264
    Abstract: Solid rinsing, cleaning and/or sanitizing compositions for various applications are provided. In particular, solid compositions include a complex of urea and an acid having desireable storage stability previously unavailable in solid urea/acid compositions. Stable solid compositions are disclosed and methods of making the same to overcome conventional limitations associated with with forming kinetically and thermodynamically stable solids that utilize urea/acid compositions.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: December 7, 2021
    Assignee: Ecolab USA Inc.
    Inventors: Derrick Anderson, Victor Fuk-Pong Man, Paul Christian, Meghan Babcock, Altony J. Miralles
  • Patent number: 11185509
    Abstract: A solid preparation includes a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, which is stable to light even without light shielding coating. The solid preparation includes an active ingredient composed of a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, and one or more stabilizing agents selected from the group consisting of n-propyl gallate, sodium hydrogensulfite, dibutylhydroxytoluene, butylhydroxyanisole, tocopherol and D-isoascorbic acid, wherein the amount of the above active ingredient is 0.00001 to 0.01% by weight of the solid preparation, and the amount of the above stabilizing agent is 0.005 to 5% by weight of the solid preparation.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: November 30, 2021
    Assignee: Toray Industries, Inc.
    Inventors: Suguru Takaki, Satoshi Minakami, Kotoe Ohta
  • Patent number: 11185542
    Abstract: Anti-cancer therapies involving non-cytotoxic dopamine beta-hydroxylase (DBH) inhibitors, such as nepicastat, etamicastat, and their analogs and pharmaceutically acceptable salts, and non-cytotoxic serotonin receptor antagonists, such as amperozide and its analogs and pharmaceutically acceptable salts are provided. The non-cytotoxic DBH inhibitors and serotonin receptor antagonists can be administered alone or in combination with one or more additional anti-cancer agents or anti-cancer therapies. Pharmaceutical compositions and combinations containing the non-cytotoxic DBH inhibitors and serotonin receptor antagonists and one or more additional anti-cancer agents, and methods of treating cancer using the pharmaceutical compositions and combinations are also provided.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: November 30, 2021
    Assignee: Jiangsu Yahong Meditech Co., Ltd.
    Inventors: Ke Pan, Qiang Li